Alisa Jennifer Prager, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Glaucoma | 7 | 2022 | 1185 | 1.220 |
Why?
|
Visual Fields | 3 | 2021 | 1062 | 0.890 |
Why?
|
Visual Field Tests | 3 | 2021 | 411 | 0.770 |
Why?
|
Neurocutaneous Syndromes | 1 | 2021 | 53 | 0.710 |
Why?
|
Arteriovenous Fistula | 1 | 2021 | 319 | 0.580 |
Why?
|
Eye Diseases | 2 | 2022 | 653 | 0.560 |
Why?
|
Tomography, Optical Coherence | 3 | 2022 | 2917 | 0.540 |
Why?
|
Macula Lutea | 1 | 2017 | 177 | 0.520 |
Why?
|
Fluorescein Angiography | 1 | 2021 | 1059 | 0.500 |
Why?
|
Retinal Vessels | 1 | 2021 | 852 | 0.490 |
Why?
|
Glaucoma, Open-Angle | 1 | 2021 | 738 | 0.460 |
Why?
|
Vision Disorders | 1 | 2021 | 1088 | 0.440 |
Why?
|
Retinal Ganglion Cells | 1 | 2017 | 811 | 0.370 |
Why?
|
Visual Acuity | 2 | 2017 | 2672 | 0.360 |
Why?
|
Disease Management | 1 | 2021 | 2508 | 0.350 |
Why?
|
Medicare | 2 | 2018 | 6770 | 0.320 |
Why?
|
Brain Diseases | 1 | 2015 | 1545 | 0.250 |
Why?
|
Self Report | 1 | 2016 | 3725 | 0.230 |
Why?
|
Health Care Costs | 1 | 2016 | 3242 | 0.210 |
Why?
|
Patient Acceptance of Health Care | 1 | 2016 | 3205 | 0.200 |
Why?
|
Magnetic Resonance Imaging | 3 | 2021 | 36429 | 0.200 |
Why?
|
Hospitalization | 2 | 2018 | 10721 | 0.190 |
Why?
|
Medicare Part D | 2 | 2016 | 355 | 0.180 |
Why?
|
Brain Neoplasms | 4 | 2015 | 9031 | 0.180 |
Why?
|
beta-Alanine | 1 | 2021 | 82 | 0.180 |
Why?
|
Ocular Hypertension | 1 | 2022 | 209 | 0.180 |
Why?
|
Quality of Life | 4 | 2022 | 13367 | 0.170 |
Why?
|
Blastomycosis | 1 | 2019 | 14 | 0.170 |
Why?
|
Glioma | 1 | 2015 | 3455 | 0.170 |
Why?
|
Benzoates | 1 | 2021 | 212 | 0.170 |
Why?
|
Fundus Oculi | 1 | 2021 | 556 | 0.160 |
Why?
|
Neoplasm Recurrence, Local | 2 | 2015 | 9280 | 0.160 |
Why?
|
Dacryocystitis | 1 | 2019 | 68 | 0.160 |
Why?
|
Scotoma | 1 | 2017 | 130 | 0.130 |
Why?
|
Health Plan Implementation | 2 | 2016 | 337 | 0.130 |
Why?
|
Vision, Binocular | 1 | 2017 | 226 | 0.130 |
Why?
|
Disease Progression | 3 | 2022 | 13510 | 0.110 |
Why?
|
Hepatocyte Growth Factor | 1 | 2013 | 271 | 0.100 |
Why?
|
Dacarbazine | 1 | 2015 | 559 | 0.100 |
Why?
|
Osteopontin | 1 | 2013 | 301 | 0.100 |
Why?
|
Insulin-Like Growth Factor Binding Protein 3 | 1 | 2013 | 416 | 0.100 |
Why?
|
Health Services Research | 1 | 2018 | 1812 | 0.090 |
Why?
|
Prostatic Neoplasms | 1 | 2013 | 11122 | 0.090 |
Why?
|
Drug Costs | 2 | 2016 | 1183 | 0.090 |
Why?
|
Confidence Intervals | 1 | 2016 | 2927 | 0.090 |
Why?
|
Cost Savings | 1 | 2015 | 913 | 0.090 |
Why?
|
Cross-Sectional Studies | 4 | 2018 | 26127 | 0.080 |
Why?
|
Brain Stem Neoplasms | 1 | 2011 | 190 | 0.080 |
Why?
|
Area Under Curve | 1 | 2013 | 1638 | 0.080 |
Why?
|
Antihypertensive Agents | 2 | 2016 | 2024 | 0.080 |
Why?
|
Metabolic Networks and Pathways | 1 | 2013 | 789 | 0.080 |
Why?
|
Prescription Drugs | 1 | 2016 | 631 | 0.080 |
Why?
|
Radiotherapy | 1 | 2015 | 1499 | 0.070 |
Why?
|
Glioblastoma | 2 | 2013 | 3482 | 0.070 |
Why?
|
Ophthalmic Solutions | 2 | 2022 | 313 | 0.070 |
Why?
|
Aged | 10 | 2018 | 169310 | 0.070 |
Why?
|
Humans | 20 | 2022 | 761572 | 0.070 |
Why?
|
Interferon-alpha | 1 | 2011 | 921 | 0.070 |
Why?
|
Kidney Transplantation | 1 | 2022 | 4235 | 0.070 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2013 | 3810 | 0.070 |
Why?
|
Artificial Intelligence | 1 | 2021 | 2578 | 0.070 |
Why?
|
Molecular Imaging | 1 | 2013 | 815 | 0.070 |
Why?
|
Female | 15 | 2021 | 392686 | 0.070 |
Why?
|
Polyethylene Glycols | 1 | 2011 | 1189 | 0.060 |
Why?
|
ROC Curve | 1 | 2013 | 3579 | 0.060 |
Why?
|
Radiation Injuries | 1 | 2013 | 1189 | 0.060 |
Why?
|
Diagnosis, Differential | 1 | 2021 | 12975 | 0.060 |
Why?
|
Male | 14 | 2018 | 360842 | 0.060 |
Why?
|
Insurance Coverage | 1 | 2016 | 1940 | 0.060 |
Why?
|
Comorbidity | 1 | 2018 | 10508 | 0.060 |
Why?
|
Prostate-Specific Antigen | 1 | 2013 | 2469 | 0.060 |
Why?
|
Diabetes Mellitus | 1 | 2022 | 5841 | 0.060 |
Why?
|
Odds Ratio | 1 | 2016 | 9646 | 0.060 |
Why?
|
Neurosurgical Procedures | 1 | 2015 | 2072 | 0.060 |
Why?
|
Medication Adherence | 1 | 2015 | 2176 | 0.060 |
Why?
|
Radiosurgery | 1 | 2013 | 1342 | 0.060 |
Why?
|
Aged, 80 and over | 3 | 2018 | 58986 | 0.050 |
Why?
|
Databases, Factual | 1 | 2018 | 7967 | 0.050 |
Why?
|
Longitudinal Studies | 2 | 2016 | 14607 | 0.050 |
Why?
|
Middle Aged | 6 | 2021 | 220920 | 0.050 |
Why?
|
Hypertension | 1 | 2022 | 8540 | 0.050 |
Why?
|
United States | 4 | 2018 | 72335 | 0.050 |
Why?
|
Socioeconomic Factors | 1 | 2016 | 7827 | 0.050 |
Why?
|
Sensitivity and Specificity | 2 | 2013 | 14666 | 0.050 |
Why?
|
Retrospective Studies | 3 | 2022 | 80646 | 0.050 |
Why?
|
Logistic Models | 1 | 2016 | 13255 | 0.050 |
Why?
|
Diffusion Magnetic Resonance Imaging | 1 | 2012 | 2791 | 0.050 |
Why?
|
Antineoplastic Agents | 2 | 2015 | 13642 | 0.040 |
Why?
|
Neoplasm Staging | 1 | 2013 | 11121 | 0.040 |
Why?
|
Electromagnetic Fields | 1 | 2000 | 296 | 0.040 |
Why?
|
Incidence | 1 | 2016 | 21355 | 0.040 |
Why?
|
Sickness Impact Profile | 1 | 2017 | 299 | 0.030 |
Why?
|
Prognosis | 2 | 2013 | 29629 | 0.030 |
Why?
|
Intraocular Pressure | 1 | 2022 | 1294 | 0.030 |
Why?
|
Prospective Studies | 2 | 2017 | 54426 | 0.030 |
Why?
|
Antibodies, Monoclonal | 1 | 2012 | 9177 | 0.030 |
Why?
|
Follow-Up Studies | 1 | 2017 | 39107 | 0.030 |
Why?
|
Risk Assessment | 1 | 2016 | 23996 | 0.030 |
Why?
|
Cysts | 1 | 2019 | 681 | 0.030 |
Why?
|
Financing, Personal | 1 | 2016 | 309 | 0.030 |
Why?
|
Visual Cortex | 1 | 2000 | 1108 | 0.020 |
Why?
|
Drug Utilization | 1 | 2015 | 1188 | 0.020 |
Why?
|
Tissue Distribution | 1 | 2013 | 2264 | 0.020 |
Why?
|
Graft Rejection | 1 | 2022 | 4446 | 0.020 |
Why?
|
Necrosis | 1 | 2013 | 1611 | 0.020 |
Why?
|
Gene Amplification | 1 | 2013 | 1089 | 0.020 |
Why?
|
Income | 1 | 2016 | 1877 | 0.020 |
Why?
|
Brain | 1 | 2013 | 27120 | 0.020 |
Why?
|
Preoperative Care | 1 | 2013 | 2242 | 0.010 |
Why?
|
Up-Regulation | 1 | 2013 | 4124 | 0.010 |
Why?
|
Lacrimal Apparatus | 1 | 1966 | 223 | 0.010 |
Why?
|
Drug Administration Schedule | 1 | 2011 | 4853 | 0.010 |
Why?
|
Health Expenditures | 1 | 2016 | 2366 | 0.010 |
Why?
|
Recombinant Proteins | 1 | 2011 | 6534 | 0.010 |
Why?
|
Disease-Free Survival | 1 | 2011 | 6815 | 0.010 |
Why?
|
Phosphenes | 1 | 2000 | 41 | 0.010 |
Why?
|
Combined Modality Therapy | 1 | 2011 | 8528 | 0.010 |
Why?
|
Sensory Thresholds | 1 | 2000 | 377 | 0.010 |
Why?
|
Dose-Response Relationship, Radiation | 1 | 2000 | 882 | 0.010 |
Why?
|
Adolescent | 3 | 2013 | 88324 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2013 | 20099 | 0.010 |
Why?
|
Electric Stimulation | 1 | 2000 | 1736 | 0.010 |
Why?
|
Electromyography | 1 | 2000 | 1394 | 0.010 |
Why?
|
Reference Values | 1 | 2000 | 4920 | 0.010 |
Why?
|
Motor Cortex | 1 | 2000 | 1007 | 0.010 |
Why?
|
Adult | 4 | 2013 | 221203 | 0.010 |
Why?
|
Infant | 2 | 2011 | 36192 | 0.010 |
Why?
|
Child, Preschool | 2 | 2011 | 42230 | 0.010 |
Why?
|
Transcranial Magnetic Stimulation | 1 | 2000 | 1473 | 0.010 |
Why?
|
Lung Neoplasms | 1 | 2013 | 13382 | 0.000 |
Why?
|
Aging | 1 | 1966 | 8711 | 0.000 |
Why?
|
Young Adult | 1 | 2013 | 59255 | 0.000 |
Why?
|
Breast Neoplasms | 1 | 2013 | 21017 | 0.000 |
Why?
|
Child | 2 | 2011 | 80156 | 0.000 |
Why?
|
Conjunctivitis | 1 | 1966 | 155 | 0.000 |
Why?
|
Atrophy | 1 | 1966 | 1633 | 0.000 |
Why?
|